PERCORTEN by Novartis is clinical pharmacology: desoxycorticosterone pivalate (docp), like other adrenocorticoid hormones, is thought to act by controlling the rate of synthesis of proteins. First approved in 1942.
Drug data last refreshed Yesterday · AI intelligence enriched 3w ago
PERCORTEN (desoxycorticosterone pivalate/DOCP) is a long-acting mineralocorticoid ester administered as an intramuscular pellet implant for treatment of hypoadrenocorticism in animals. It works by controlling protein synthesis through steroid-receptor complexes that bind to chromatin, primarily increasing renal tubular sodium reabsorption and extracellular fluid volume to prevent hypotensive shock and pre-renal azotemia. This mechanism mirrors the natural hormone aldosterone and restores critical electrolyte and fluid balance in adrenal-insufficient patients.
Product approaching end-of-life with minimal competitive pressure (30%), suggesting consolidation of team resources and focus on retention rather than expansion.
CLINICAL PHARMACOLOGY: Desoxycorticosterone pivalate (DOCP), like other adrenocorticoid hormones, is thought to act by controlling the rate of synthesis of proteins. It reacts with receptor proteins in the cytoplasm to form a steroid-receptor complex. This complex moves into the nucleus, where it…
Worked on PERCORTEN at Novartis? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Zero linked job openings indicate minimal hiring activity on PERCORTEN; roles available are primarily in commercial maintenance and regulatory compliance within Novartis's veterinary division. This is a legacy-managed product with stable but limited career growth potential, best suited for professionals seeking niche expertise in mineralocorticoid therapy or veterinary pharmaceuticals rather than high-visibility innovation roles.